Efficacy of Recombinant Interferon-α-2b Application in Children with Virus-Induced Bronchial Asthma Phenotype

Abstract

The paper presents the results of the study of the efficacy of recombinant interferon α-2b use in children with bronchial asthma, who often suffer from acute respiratory viral infection (ARVI). It is established that under the influence of recombinant interferon-α-2b use for prolonged scheme, the content of INF-γ increases, the concentration of IgE decreases, with the tendency to normalization of the oxidant-antioxidant status. The clinical criteria of recombinant interferon-α-2b efficcacy are 2.4-fold decrease in ARVI incidence, 3.3-fold reduction in the frequency of bronchial asthma against ARVI, which has a positive effect on the clinical course of bronchial asthma. The period of remission in patients increased up to 4–6 months, duration of seizure period decreased.

Keywords

• children
• bronchial asthma
• recombinant interferon-α-2b
• immunit
• efficacy of treatment